Similar to studies evaluating TCL1 in CLL43–45, the apparent inter-patient variability suggests multiple factors likely contribute to dysregulation of MTCP1 expression; where loss of microRNA-mediated negative regulation or MTCP1 upregulation via stimulating signals from the tumor microenvironment are primary candidates for further evaluation. Here, MTCP1 is linked to neoplasm.